<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872467</url>
  </required_header>
  <id_info>
    <org_study_id>14-3053</org_study_id>
    <nct_id>NCT02872467</nct_id>
  </id_info>
  <brief_title>Prenatal Cocaine, Nasal Oxytocin, and Maternal Psychophysiology</brief_title>
  <acronym>NOX</acronym>
  <official_title>Prenatal Cocaine, Nasal Oxytocin, and Maternal Psychophysiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation of Hope, North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study the effects of nasal oxytocin administration on&#xD;
      maternal behaviors that may be influenced by cocaine use during pregnancy. 32 mothers with&#xD;
      prenatal use of cocaine during the current pregnancy will be studied at 3-6 months&#xD;
      postpartum, when they will complete 3 study visits, a 2-week double-blind trial of twice&#xD;
      daily nasal spray (oxytocin or placebo) and 4 telephone interviews. All information collected&#xD;
      is confidential.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participation for mothers when they are 3-6 months postpartum includes:&#xD;
&#xD;
        -  Visit 1: Questionnaires and interviews about participants' health, pregnancy, moods,&#xD;
           psychological history and drug use during pregnancy and postpartum.&#xD;
&#xD;
        -  Visit 2: Pregnancy &amp; drug tests (results are confidential), blood samples and vital&#xD;
           signs, video-taped mother-infant interaction, speech task, instruction re: using nasal&#xD;
           spray (oxytocin or placebo) &amp; self-administration of first nasal spray dose, followed by&#xD;
           90 minutes of monitoring.&#xD;
&#xD;
        -  At-home nasal spray: Twice daily (before breakfast and supper) nasal spray&#xD;
           self-administration for 14 days.&#xD;
&#xD;
        -  Visit 3: Pregnancy &amp; drug tests (results are confidential), blood samples and vital&#xD;
           signs, video-taped mother-infant interaction, speech task, interviews and questionnaires&#xD;
           about mothers' experience with the nasal spray, and changes in mood or physical&#xD;
           discomfort during the 2-weeks when taking the nasal spray.&#xD;
&#xD;
        -  3 telephone interviews while subjects are taking nasal spray, and 1 post-trail telephone&#xD;
           follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Due to COVID-19 restrictions, recruitment suspended until at least Fall, 2021&#xD;
  </why_stopped>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effects of a 2-week trial of twice nasal oxytocin compared with placebo on maternal sensitivity</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effects of a 2-week trial of nasal oxytocin compared with placebo on maternal reactivity to a social stressor indexed by change in vascular resistance from pre- to post-test nasal spray.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effects of a 2-week trial of nasal oxytocin compared with placebo on maternal reactivity to a social stressor indexed by change in plasma norepinephrine.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effects of a 2-week trial of nasal oxytocin compared with placebo on maternal reactivity to a social stressor indexed by self-reported affective ratings.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Substance Abuse Problem</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Syntocinon treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syntocinon treatment</intervention_name>
    <description>24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).</description>
    <arm_group_label>Syntocinon treatment</arm_group_label>
    <other_name>Nasal Oxytocin treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  3-6 months postpartum at start of testing&#xD;
&#xD;
          -  Cocaine use during current pregnancy (by self-report or medical record of prenatal&#xD;
             urine toxicology)&#xD;
&#xD;
          -  Exclusive Formula-feeding for all infant milk feedings (no infant feeds will be breast&#xD;
             milk)&#xD;
&#xD;
          -  Healthy singleton pregnancy&#xD;
&#xD;
          -  English fluency that will allow informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or plans to become pregnant during participation in the study&#xD;
&#xD;
          -  Not using effective birth control methods to prevent pregnancy&#xD;
&#xD;
          -  Breastfeeding for any infant milk feedings&#xD;
&#xD;
          -  Mother is not currently living with the infant during the trial period&#xD;
&#xD;
          -  Multiple birth (twin, triplet or greater)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Grewen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC School of Medicine, Dept. of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC School of Medicine, Medical School Wing D</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cocaine</keyword>
  <keyword>Mothers</keyword>
  <keyword>Pregnant women</keyword>
  <keyword>Postpartum women</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Substance use disorders</keyword>
  <keyword>Substance abuse</keyword>
  <keyword>Prenatal substance use</keyword>
  <keyword>stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

